Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 23
Encontrada(s) 1 página(s)

Repisalud
Publicación Artículo científico (JournalArticle)

RANK links senescence to stemness in the mammary epithelia, delaying tumor onset but increasing tumor aggressiveness.

  • Benítez, Sandra
  • Cordero, Alex
  • Santamaría, Patricia G
  • Redondo-Pedraza, Jaime
  • Rocha, Ana S
  • Collado-Solé, Alejandro
  • Jimenez, Maria
  • Sanz-Moreno, Adrian
  • Yoldi, Guillermo
  • Santos, Juliana C
  • De Benedictis, Ilaria
  • Gómez-Aleza, Clara
  • Da Silva-Álvarez, Sabela
  • Troulé, Kevin
  • Gómez-López, Gonzalo
  • Alcazar, Noelia
  • Palmero, Ignacio
  • Collado, Manuel
  • Serrano, Manuel
  • Gonzalez-Suarez, Eva
  • Benítez, Sandra
  • Cordero, Alex
  • Santamaría, Patricia G
  • Redondo-Pedraza, Jaime
  • Rocha, Ana S
  • Collado-Solé, Alejandro
  • Jimenez, Maria
  • Sanz-Moreno, Adrian
  • Yoldi, Guillermo
  • Santos, Juliana C
  • De Benedictis, Ilaria
  • Gómez-Aleza, Clara
  • Da Silva-Álvarez, Sabela
  • Troulé, Kevin
  • Gómez-López, Gonzalo
  • Alcazar, Noelia
  • Palmero, Ignacio
  • Collado, Manuel
  • Serrano, Manuel
  • Gonzalez-Suarez, Eva
Rank signaling enhances stemness in mouse and human mammary epithelial cells (MECs) and mediates mammary tumor initiation. Mammary tumors initiated by oncogenes or carcinogen exposure display high levels of Rank and Rank pathway inhibitors have emerged as a new strategy for breast cancer prevention and treatment. Here, we show that ectopic Rank expression in the mammary epithelia unexpectedly delays tumor onset and reduces tumor incidence in the oncogene-driven Neu and PyMT models. Mechanistically, we have found that ectopic expression of Rank or exposure to Rankl induces senescence, even in the absence of other oncogenic mutations. Rank leads to DNA damage and senescence through p16/p19. Moreover, RANK-induced senescence is essential for Rank-driven stemness, and although initially translates into delayed tumor growth, eventually promotes tumor progression and metastasis. We uncover a dual role for Rank in the mammary epithelia: Rank induces senescence and stemness, delaying tumor initiation but increasing tumor aggressiveness.
Repisalud
Publicación Artículo científico (JournalArticle)

Luminal Rank loss decreases cell fitness leading to basal cell bipotency in parous mammary glands.

  • Rocha, Ana Sofia
  • Collado-Solé, Alejandro
  • Graña-Castro, Osvaldo
  • Redondo-Pedraza, Jaime
  • Soria-Alcaide, Gonzalo
  • Cordero, Alex
  • Santamaría, Patricia G
  • González-Suárez, Eva
Rank signaling pathway regulates mammary gland homeostasis and epithelial cell differentiation. Although Rank receptor is expressed by basal cells and luminal progenitors, its role in each individual cell lineage remains unclear. By combining temporal/lineage specific Rank genetic deletion with lineage tracing techniques, we found that loss of luminal Rank reduces the luminal progenitor pool and leads to aberrant alveolar-like differentiation with high protein translation capacity in virgin mammary glands. These Rank-deleted luminal cells are unable to expand during the first pregnancy, leading to lactation failure and impairment of protein synthesis potential in the parous stage. The unfit parous Rank-deleted luminal cells in the alveoli are progressively replaced by Rank-proficient cells early during the second pregnancy, thereby restoring lactation. Transcriptomic analysis and functional assays point to the awakening of basal bipotency after pregnancy by the induction of Rank/NF-κB signaling in basal parous cell to restore lactation and tissue homeostasis.
Repisalud
Publicación Artículo científico (JournalArticle)

RANK signaling increases after anti-HER2 therapy contributing to the emergence of resistance in HER2-positive breast cancer.

  • Sanz-Moreno, Adrián
  • Palomeras, Sonia
  • Pedersen, Kim
  • Morancho, Beatriz
  • Pascual, Tomas
  • Galván, Patricia
  • Benítez, Sandra
  • Gomez-Miragaya, Jorge
  • Ciscar, Marina
  • Jimenez, Maria
  • Pernas, Sonia
  • Petit, Anna
  • Soler-Monsó, María Teresa
  • Viñas, Gemma
  • Alsaleem, Mansour
  • Rakha, Emad A
  • Green, Andrew R
  • Santamaria, Patricia G
  • Mulder, Celine
  • Lemeer, Simone
  • Arribas, Joaquin
  • Prat, Aleix
  • Puig, Teresa
  • Gonzalez-Suarez, Eva
  • Sanz-Moreno, Adrián
  • Palomeras, Sonia
  • Pedersen, Kim
  • Morancho, Beatriz
  • Pascual, Tomas
  • Galván, Patricia
  • Benítez, Sandra
  • Gomez-Miragaya, Jorge
  • Ciscar, Marina
  • Jimenez, Maria
  • Pernas, Sonia
  • Petit, Anna
  • Soler-Monsó, María Teresa
  • Viñas, Gemma
  • Alsaleem, Mansour
  • Rakha, Emad A
  • Green, Andrew R
  • Santamaria, Patricia G
  • Mulder, Celine
  • Lemeer, Simone
  • Arribas, Joaquin
  • Prat, Aleix
  • Puig, Teresa
  • Gonzalez-Suarez, Eva
Around 15-20% of primary breast cancers are characterized by HER2 protein overexpression and/or HER2 gene amplification. Despite the successful development of anti-HER2 drugs, intrinsic and acquired resistance represents a major hurdle. This study was performed to analyze the RANK pathway contribution in HER2-positive breast cancer and anti-HER2 therapy resistance.
Repisalud
Publicación Artículo científico (JournalArticle)

Inhibition of RANK signaling as a potential immunotherapy in breast cancer.

  • Gómez-Aleza, C
  • González-Suárez, E
RANK signaling in mouse mammary tumor cells exerts an immunosuppressive environment by promoting the infiltration of pro-tumorigenic neutrophils and preventing CD8 T cell recruitment. Single-agent denosumab led to an increased tumor immune infiltration by lymphocytes and CD8 + T cells in breast cancer patients, supporting the immunomodulatory role of RANK signaling.
Repisalud
Publicación Artículo científico (JournalArticle)

Inhibition of RANK signaling in breast cancer induces an anti-tumor immune response orchestrated by CD8+ T cells.

  • Gómez-Aleza, Clara
  • Nguyen, Bastien
  • Yoldi, Guillermo
  • Ciscar, Marina
  • Barranco, Alexandra
  • Hernández-Jiménez, Enrique
  • Maetens, Marion
  • Salgado, Roberto
  • Zafeiroglou, Maria
  • Pellegrini, Pasquale
  • Venet, David
  • Garaud, Soizic
  • Trinidad, Eva M
  • Benítez, Sandra
  • Vuylsteke, Peter
  • Polastro, Laura
  • Wildiers, Hans
  • Simon, Philippe
  • Lindeman, Geoffrey
  • Larsimont, Denis
  • Van den Eynden, Gert
  • Velghe, Chloé
  • Rothé, Françoise
  • Willard-Gallo, Karen
  • Michiels, Stefan
  • Muñoz, Purificación
  • Walzer, Thierry
  • Planelles, Lourdes
  • Penninger, Josef
  • Azim, Hatem A
  • Loi, Sherene
  • Piccart, Martine
  • Sotiriou, Christos
  • González-Suárez, Eva
Most breast cancers exhibit low immune infiltration and are unresponsive to immunotherapy. We hypothesized that inhibition of the receptor activator of nuclear factor-κB (RANK) signaling pathway may enhance immune activation. Here we report that loss of RANK signaling in mouse tumor cells increases leukocytes, lymphocytes, and CD8+ T cells, and reduces macrophage and neutrophil infiltration. CD8+ T cells mediate the attenuated tumor phenotype observed upon RANK loss, whereas neutrophils, supported by RANK-expressing tumor cells, induce immunosuppression. RANKL inhibition increases the anti-tumor effect of immunotherapies in breast cancer through a tumor cell mediated effect. Comparably, pre-operative single-agent denosumab in premenopausal early-stage breast cancer patients from the Phase-II D-BEYOND clinical trial (NCT01864798) is well tolerated, inhibits RANK pathway and increases tumor infiltrating lymphocytes and CD8+ T cells. Higher RANK signaling activation in tumors and serum RANKL levels at baseline predict these immune-modulatory effects. No changes in tumor cell proliferation (primary endpoint) or other secondary endpoints are observed. Overall, our preclinical and clinical findings reveal that tumor cells exploit RANK pathway as a mechanism to evade immune surveillance and support the use of RANK pathway inhibitors to prime luminal breast cancer for immunotherapy.
Repisalud
Publicación Artículo científico (JournalArticle)

Rank ectopic expression in the presence of Neu and MMTV oncogenes alters mammary epithelial cell populations and their tumorigenic potential.

  • Cordero, Alex
  • Santamaría, Patricia G
  • González-Suárez, Eva
Determination of the mammary epithelial cell that serves as the cell of origin for breast cancer is key to understand tumor heterogeneity and clinical management. In this study, we aimed to decipher whether Rank expression in the presence of PyMT and Neu oncogenes might affect the cell of origin of mammary gland tumors. We observed that Rank expression in PyMT+/- and Neu+/- mammary glands alters the basal and luminal mammary cell populations already in preneoplasic tissue, which may interfere with the tumor cell of origin restricting their tumorigenesis ability upon transplantation assays. In spite of this, Rank expression eventually promotes tumor aggressiveness once tumorigenesis is established.
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

RANK links senescence to stemness in the mammary epithelia, delaying tumor onset but increasing tumor aggressiveness

  • Benítez, Sandra
  • Cordero, Alex
  • Santamaría, Patricia G.
  • Redondo Pedraza, Jaime
  • Rocha, Ana S.
  • Collado-Solé, Alejandro
  • Jimenez, María
  • Sanz Moreno, Adrian
  • Yoldi, Guillermo
  • Santos, Juliana C.
  • Benedictis, Ilaria De
  • Gómez Aleza, Clara
  • Silva Álvarez, Sabela Da
  • Troulé, Kevin
  • Gómez López, Gonzalo
  • Alcazar, Noelia
  • Palmero, Ignacio
  • Collado, Manuel
  • Serrano Marugán, Manuel
  • González Suárez, Eva
Rank signaling enhances stemness in mouse and human mammary epithelial cells (MECs) and mediates mammary tumor initiation. Mammary tumors initiated by oncogenes or carcinogen exposure display high levels of Rank and Rank pathway inhibitors have emerged as a new strategy for breast cancer prevention and treatment. Here, we show that ectopic Rank expression in the mammary epithelia unexpectedly delays tumor onset and reduces tumor incidence in the oncogene-driven Neu and PyMT models. Mechanistically, we have found that ectopic expression of Rank or exposure to Rankl induces senescence, even in the absence of other oncogenic mutations. Rank leads to DNA damage and senescence through p16/p19. Moreover, RANK-induced senescence is essential for Rank-driven stemness, and although initially translates into delayed tumor growth, eventually promotes tumor progression and metastasis. We uncover a dual role for Rank in the mammary epithelia: Rank induces senescence and stemness, delaying tumor initiation but increasing tumor aggressiveness.
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

The altered transcriptome and DNA methylation profiles of docetaxel resistance in breast cancer PDX models

  • Gómez Miragaya, Jorge
  • Moran, Sebastian
  • Calleja Cervantes, Maria E.
  • Collado-Solé, Alejandro
  • Paré, Laia
  • Gómez, Antonio
  • Serra Elizalde, Violeta
  • Dobrolecki, Lacey E.
  • Lewis, Michael T.
  • Diaz-Lagares, Angel
  • Eroles, Pilar
  • Prat Aparicio, Aleix
  • Esteller, Manel, 1968-
  • González Suárez, Eva
Taxanes are standard therapy in clinical practice for metastatic breast cancer; however, primary or acquired chemoresistance are a common cause of mortality. Breast cancer patient-derived xenografts (PDX) are powerful tools for the study of cancer biology and drug treatment response. Specific DNA methylation patterns have been associated to different breast cancer subtypes but its association with chemoresistance remains unstudied. Aiming to elucidate docetaxel resistance mechanisms, we performed genome-wide DNA methylation in breast cancer PDX models, including luminal and triple-negative breast cancer (TNBC) models sensitive to docetaxel, their matched models after emergence of chemoresistance and residual disease after short-term docetaxel treatment. We found that DNA methylation profiles from breast cancer PDX models maintain the subtype-specific methylation patterns of clinical samples. Two main DNA methylation clusters were found in TNBC PDX and remain stable during the emergence of docetaxel resistance; however, some genes/pathways were differentially methylated according to docetaxel response. A DNA methylation signature of resistance able to segregate TNBC based on chemotherapy response was identified. Transcriptomic profiling of selected sensitive/resistant pairs and integrative analysis with methylation data demonstrated correlation between some differentially methylated and expressed genes in docetaxel-resistant TNBC PDX models. Multiple gene expression changes were found after the emergence of docetaxel resistance in TNBC. DNA methylation and transcriptional changes identified between docetaxel-sensitive and -resistant TNBC PDX models or residual disease may have predictive value for chemotherapy response in TNBC. IMPLICATIONS: Subtype-specific DNA methylation patterns are maintained in breast cancer PDX models. While no global methylation changes were found, we uncovered differentially DNA methylated and expressed genes/pathways associated with the emergence of docetaxel resistance in TNBC.
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

RANK signaling increases after anti-HER2 therapy contributing to the emergence of resistance in HER2-positive breast cancer

  • Sanz Moreno, Adrián
  • Palomeras, Sonia
  • Pedersen, Kim
  • Morancho, Beatriz
  • Pascual, Tomás
  • Galván, Patricia
  • Benítez, Sandra
  • Gómez Miragaya, Jorge
  • Ciscar, Marina
  • Jimenez, María
  • Pernas, Sònia
  • Petit, Anna
  • Soler, María Teresa
  • Viñas, Gemma
  • Alsaleem, Mansour
  • Rakha, Emad A.
  • Green, Andrew
  • Santamaría, Patricia G.
  • Mulder, Celine
  • Lemeer, Simone
  • Arribas, Joaquín V. (Vicente)
  • Prat Aparicio, Aleix
  • Puig, Teresa
  • González Suárez, Eva
Background: Around 15-20% of primary breast cancers are characterized by HER2 protein overexpression and/or HER2 gene amplification. Despite the successful development of anti-HER2 drugs, intrinsic and acquired resistance represents a major hurdle. This study was performed to analyze the RANK pathway contribution in HER2-positive breast cancer and anti-HER2 therapy resistance. Methods: RANK and RANKL protein expression was assessed in samples from HER2-positive breast cancer patients resistant to anti-HER2 therapy and treatment-naive patients. RANK and RANKL gene expression was analyzed in paired samples from patients treated with neoadjuvant dual HER2-blockade (lapatinib and trastuzumab) from the SOLTI-1114 PAMELA trial. Additionally, HER2-positive breast cancer cell lines were used to modulate RANK expression and analyze in vitro the contribution of RANK signaling to anti-HER2 resistance and downstream signaling. Results: RANK and RANKL proteins are more frequently detected in HER2-positive tumors that have acquired resistance to anti-HER2 therapies than in treatment-naive ones. RANK (but not RANKL) gene expression increased after dual anti-HER2 neoadjuvant therapy in the cohort from the SOLTI-1114 PAMELA trial. Results in HER2-positive breast cancer cell lines recapitulate the clinical observations, with increased RANK expression observed after short-term treatment with the HER2 inhibitor lapatinib or dual anti-HER2 therapy and in lapatinib-resistant cells. After RANKL stimulation, lapatinib-resistant cells show increased NF-κB activation compared to their sensitive counterparts, confirming the enhanced functionality of the RANK pathway in anti-HER2-resistant breast cancer. Overactivation of the RANK signaling pathway enhances ERK and NF-κB signaling and increases lapatinib resistance in different HER2-positive breast cancer cell lines, whereas RANK loss sensitizes lapatinib-resistant cells to the drug. Our results indicate that ErbB signaling is required for RANK/RANKL-driven activation of ERK in several HER2-positive cell lines. In contrast, lapatinib is not able to counteract the NF-κB activation elicited after RANKL treatment in RANK-overexpressing cells. Finally, we show that RANK binds to HER2 in breast cancer cells and that enhanced RANK pathway activation alters HER2 phosphorylation status. Conclusions: Our data support a physical and functional link between RANK and HER2 signaling in breast cancer and demonstrate that increased RANK signaling may contribute to the development of lapatinib resistance through NF-κB activation. Whether HER2-positive breast cancer patients with tumoral RANK expression might benefit from dual HER2 and RANK inhibition therapy remains to be elucidated.
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

European Network of Breast Development and Cancer turned 10 years: a growing family of mammary gland researchers

  • Koledova, Zuzana
  • Howard, Beatrice A.
  • Englund, Johanna
  • Bach, Karsten
  • Bentires-Alj, Mohamed
  • González Suárez, Eva
The European Network for Breast Development and Cancer (ENBDC), a worldwide network (http://www.enbdc.org/), celebrated its tenth anniversary with a fantastic meeting last March 15-17, 2018 in Weggis with 76 attendees.
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

Management of bone health in solid tumours: From bisphosphonates to a monoclonal antibody

  • von Moos, Roger
  • Costa, Luis
  • González Suárez, Eva
  • Terpos, Evangelos
  • Niepel, Daniela
  • Body, Jean-Jacques
Patients with solid tumours are at risk of impaired bone health from metastases and cancer therapy-induced bone loss (CTIBL). We review medical management of bone health in patients with solid tumours over the past 30 years, from first-generation bisphosphonates to the receptor activator of nuclear factor kappa B ligand (RANKL)-targeted monoclonal antibody, denosumab. In the 1980s, first-generation bisphosphonates were shown to reduce the incidence of skeletal-related events (SREs) in patients with breast cancer. Subsequently, more potent second-and third-generation bisphosphonates were developed, particularly zoledronic add (ZA). Head-to-head studies showed that ZA was significantly more effective than pamidronate for reducing SREs in patients with breast and castrate-resistant prostate cancer (CRPC), becoming the standard of care for more than a decade. The RANKL inhibitor denosumab was licensed in 2010, and head-to-head studies and integrated analyses confirmed its superiority to ZA for preventing SREs, particularly in breast cancer and CRPC. Bisphosphonates and denosumab have also been investigated for prevention of CTIBL in patients receiving hormonal therapy for breast and prostate cancer, and denosumab is licensed in this indication. Despite advances in management of bone health, several issues remain, notably the optimal time to initiate therapy, duration of therapy, and dosing frequency, and how to avoid toxicity, particularly with long-term treatment. In summary, introduction of ZA and denosumab has protected patients with bone metastasis from serious bone complications and improved their quality of life. Ongoing research will hopefully guide the optimal use of these agents to help maintain bone health in patients with solid tumours.
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

Interrogating open issues in cancer precision medicine with patient-derived xenografts

  • Byrne, Annette T.
  • Alférez, Denis G.
  • Amant, Frédéric
  • Annibali, Daniela
  • Arribas, Joaquín V. (Vicente)
  • Biankin, Andrew V.
  • Bruna, Alejandra
  • Budinská, Eva
  • Caldas, Carlos
  • Chang, David K.
  • Clarke, Robert B.
  • Clevers, Hans
  • Coukos, George
  • Dangles Marie, Virginie
  • Eckhardt, S. Gail
  • González Suárez, Eva
  • Hermans, Els
  • Hidalgo, Manuel
  • Jarzabek, Monika A.
  • Jong, Steven de
  • Jonkers, Jos
  • Kemper, Kristel
  • Lanfrancone, Luisa
  • Mælandsmo, Gunhild Mari
  • Marangoni, Elisabetta
  • Marine, Jean-Christophe
  • Medico, Enzo
  • Norum, Jens Henrik
  • Palmer, Héctor G.
  • Peeper, Daniel S.
  • Pelicci, Pier Giuseppe
  • Piris Gimenez, Alejandro
  • Roman Roman, Sergio
  • Rueda, Oscar M.
  • Seoane Suárez, Joan
  • Serra Elizalde, Violeta
  • Soucek, Laura
  • Vanhecke, Dominique
  • Villanueva Garatachea, Alberto
  • Vinolo, Emilie
  • Bertotti, Andrea
  • Trusolino, Livio
Patient-derived xenografts (PDXs) have emerged as an important platform to elucidate new treatments and biomarkers in oncology. PDX models are used to address clinically relevant questions, including the contribution of tumour heterogeneity to therapeutic responsiveness, the patterns of cancer evolutionary dynamics during tumour progression and under drug pressure, and the mechanisms of resistance to treatment. The ability of PDX models to predict clinical outcomes is being improved through mouse humanization strategies and the implementation of co-clinical trials, within which patients and PDXs reciprocally inform therapeutic decisions. This Opinion article discusses aspects of PDX modelling that are relevant to these questions and highlights the merits of shared PDX resources to advance cancer medicine from the perspective of EurOPDX, an international initiative devoted to PDX-based research.
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

RANKL inhibitors for osteosarcoma treatment: hope and caution

  • Trinidad Alvarez, Eva Maria
  • González Suárez, Eva
Chen and collaborators propose RANKL blockade for the treatment and prevention of aggressive RANKL-overexpressing osteosarcoma (OS) in humans. Here we comment the main findings, putative applications and concerns. OS is the most common primary bone cancer, which occurs primarily in children and adolescents, severely affecting survivors’ quality of life. Current treatment for newly diagnosed OS includes three main components: preoperative chemotherapy, surgical resection, and postoperative chemotherapy (1). This strategy has improved the outcome of patients with localized OS. However, patients with advanced, metastatic, and recurrent OSs continue to experience a quite poor prognosis. After aggressive treatment with both surgery and chemotherapy, the 5-year survival rate for OS patients with localized disease is about 65%, whereas it is less than 20% for patients with metastases. The use of adjuvant chemotherapy provides no survival advantage for patients with pulmonary metastases (2). So that, it is of particular importance to develop molecularly targeted therapy to treat patients with this metastatic bone malignancy, on the basis of in-depth understanding of signaling mechanisms involved in OS tumorigenesis.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

RANK links senescence to stemness in the mammary epithelia, delaying tumor onset but increasing tumor aggressiveness

  • Benítez, Sandra
  • Cordero, Alex
  • Santamaría, Patricia G.
  • Redondo-Pedraza, Jaime
  • Rocha, Ana S.
  • Collado-Solé, Alejandro
  • Jiménez, María
  • Sanz-Moreno, Adrián
  • Yoldi, Guillermo
  • Santos, Juliana C.
  • Benedictis, Ilaria De
  • Gómez-Aleza, Clara
  • Silva-Alvarez, S. da
  • Troulé, Kevin
  • Gómez-López, Gonzalo
  • Alcázar, Noelia
  • Palmero, Ignacio
  • Collado, Manuel
  • Serrano, Manuel
  • González-Suarez, Eva
© 2021 The Authors., Rank signaling enhances stemness in mouse and human mammary epithelial cells (MECs) and mediates mammary tumor initiation. Mammary tumors initiated by oncogenes or carcinogen exposure display high levels of Rank and Rank pathway inhibitors have emerged as a new strategy for breast cancer prevention and treatment. Here, we show that ectopic Rank expression in the mammary epithelia unexpectedly delays tumor onset and reduces tumor incidence in the oncogene-driven Neu and PyMT models. Mechanistically, we have found that ectopic expression of Rank or exposure to Rankl induces senescence, even in the absence of other oncogenic mutations. Rank leads to DNA damage and senescence through p16/p19. Moreover, RANK-induced senescence is essential for Rank-driven stemness, and although initially translates into delayed tumor growth, eventually promotes tumor progression and metastasis. We uncover a dual role for Rank in the mammary epithelia: Rank induces senescence and stemness, delaying tumor initiation but increasing tumor aggressiveness., This work was supported by grants to E. González-Suárez by the Agencia Estatal de Investigación (AEI) (SAF2014-55997-R, SAF2017-86117-R) co-funded by FEDER funds/European Regional Development Fund (ERDF) (a way to build Europe), by the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (grant agreement no. 682935), and by the Fundació La Marató de TV3. We thank CERCA Programme/Generalitat de Catalunya for institutional support. S. Benítez was a recipient of an FPI, A. Collado-Solé holds an FPU from the MICINN and J Redondo-Pedraza is a recipient of an FPI Severo Ochoa Fellowship. We are grateful to Amgen for providing Rankl and Rankt+/tg mice.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

RANK is a poor prognosis marker and a therapeutic target in ER‐negative postmenopausal breast cancer

  • Ciscar, Marina
  • Trinidad, Eva M.
  • Pérez-Chacón, Gema
  • Alsaleem, Mansour
  • Jiménez, María
  • Jiménez-Santos, María J.
  • Pérez-Montoyo, Héctor
  • Sanz-Moreno, Adrián
  • Vethencourt, Andrea
  • Toss, Michael
  • Petit, Anna
  • Soler-Monso, María T.
  • López, Victor
  • Gómez-Miragaya, Jorge
  • Gómez-Aleza, Clara
  • Dobrolecki, Lacey E.
  • Lewis, Michael T.
  • Bruna, Alejandra
  • Mouron, Silvana
  • Quintela-Fandino, Miguel
  • Al-Shahrour, Fátima
  • Martínez-Aranda, Antonio
  • Sierra, Angels
  • Green, Andrew R.
  • Rakha, Emad
  • González-Suarez, Eva
Despite strong preclinical data, the therapeutic benefit of the RANKL inhibitor, denosumab, in breast cancer patients, beyond the bone, is unclear. Aiming to select patients who may benefit from denosumab, we hereby analyzed RANK and RANKL protein expression in more than 2,000 breast tumors (777 estrogen receptor‐negative, ER−) from four independent cohorts. RANK protein expression was more frequent in ER− tumors, where it associated with poor outcome and poor response to chemotherapy. In ER− breast cancer patient‐derived orthoxenografts (PDXs), RANKL inhibition reduced tumor cell proliferation and stemness, regulated tumor immunity and metabolism, and improved response to chemotherapy. Intriguingly, tumor RANK protein expression associated with poor prognosis in postmenopausal breast cancer patients, activation of NFKB signaling, and modulation of immune and metabolic pathways, suggesting that RANK signaling increases after menopause. Our results demonstrate that RANK protein expression is an independent biomarker of poor prognosis in postmenopausal and ER− breast cancer patients and support the therapeutic benefit of RANK pathway inhibitors, such as denosumab, in breast cancer patients with RANK+ ER− tumors after menopause., We thank Miguel Angel Pujana,Christian Tebe and Judith Pe~nafiel for the analyses of theIDBandCNIOcohorts, Sergi Velasco and Purificaci on Mu~noz for feedback about the manu-script. Work in the laboratory of EG-S has received funding from the SpanishMinisterio de Ciencia, Innovaci on y Universidades, which is part of AgenciaEstatal de Investigaci on (AEI) (SAF2014-55997-R, SAF2017-86117-R, andPID2020-116441GB-I00), the ISCIII (PIE13/00022) co-funded by EuropeanRegional Development Fund, a Career Catalyst Grant from the Susan KomenFoundation (CCR13262449), the Catalan Government2017SGR00665, co-funded by FEDER funds/European Regional Development Fund (ERDF) (a wayto build Europe), the European Research Council (ERC) under the EuropeanUnion’s Horizon2020research and innovation program (grant agreement no.682935), This study has been partially funded by Amgen Inc. EMT had receiveda Juan de la Cierva-Incorporaci on grant from Spanish Ministry of Science andInnovation (IJCI-2017-31564) and MG a PERIS contract from the Departamentof Salut de la Generalitat de Catalunya. The IDIBELL samples collection wasgranted by the Spanish Ministry of Health and Consumer Affairs FIS-PI14/00336from the I+D+I National Plan with the financial support from ISCIII-Subdirecci on General de Evaluaci on and the Fondo Europeo de DesarrolloRegional (FEDER). The generation of PDX models in the Lewis laboratory wassupported in part by NIH/NCI grants U54CA224076(MTL), U24CA226110(toMTL), P50CA186784(MTL) (Dan L. Duncan Cancer Center). This work was alsosupported by a Core Facility grant from the Cancer Prevention and ResearchInstitute of Texas (CPRIT Core Facilities Support Grant RP170691), Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Microglia Rank signaling regulates GnRH neuronal function and the hypothalamic-pituitary-gonadal axis

  • Collado-Sole, Alejandro
  • Borjini, Nozha
  • Zhai, Jing
  • Ruiz-Pino, Francisco
  • Soria-Alcaide, Gonzalo
  • Folgueira, Cintia
  • García-Vilela, Celia
  • Romero-de la Rosa, Beatriz
  • López, Víctor
  • Zouaghi, Yassine
  • Jacobs, An
  • Mora-Romero, Bella
  • Barranco, Alexandra
  • Yoldi, Guillermo
  • Rizzoti, Karine
  • Sabio, Guadalupe
  • Pérez-Chacón, Gema
  • Santamaría, Patricia G.
  • Esteban, José Antonio
  • Journiac, Nathalie
  • Prevot, Vincent
  • Pascual Bravo, Alberto
  • Fernández-Chacón, Rafael
  • Tena-Sempere, Manuel
  • Pitteloud, Nelly
  • González-Suárez, Eva
[Data, code, and materials availability] The scRNA-seq results obtained in this work have been deposited at Gene Expression Omnibus, GSE240379. Mouse strains used in this study are subject to a Material Transfer Agreement and can be shared upon reasonable request and in accordance with the corresponding institutional regulations. The rest of the data used in the preparation of the manuscript are available in the main text or in the supplementary materials., The hypothalamic-pituitary-gonadal axis (HPG) controls pubertal development, sexual maturation, and fertility. We identified a role of hypothalamic microglia in controlling the HPG axis through receptor activator of nuclear factor κB (Rank) signaling. Whole-body and microglia Rank (mouse) depletion led to hypogonadotropic hypogonadism (HH) resulting from an alteration in gonadotropin-releasing hormone (GnRH) neuron function. In addition, we identified rare gene variants of RANK (human) in patients with HH. Transcriptional profiling upon Rank loss revealed defective microglia activation and morphological alterations in the median eminence, decreasing the contacts and engulfment of GnRH terminal projections and impairing GnRH neuronal responses to kisspeptin. Overall, our data uncover the microglia as regulator of GnRH neuronal function through Rank signaling, with potential implications for reproductive maturation and fertility., This work was supported by grants from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program (grant agreement no. 682935, EGS); CaixaResearch Health 2023 grants from the “la Caixa” Foundation (no. HR23-00361, EGS); Comunidad Autónoma de Madrid S2022/BMD-7393 (EGS) and the Spanish Ministry of Science and Innovation through the Agencia Estatal de Investigación (AEI) (SAF2017-86117-R, PID2020-116441GB-I00, and PID2023-152798OB-I00; EGS), cofunded by FEDER/European Regional Development Fund (ERDF) (“A way to build Europe”). Grant PID2023-149244NB-I00 was awarded to M.T.-S. Additional support was provided by the Spanish Agencia Estatal de Investigación and the Ministerio de Ciencia, Innovación y Universidades, and the European Regional Development Fund (ERDF) (MICIU/AEI/10.13039/501100011033; FEDER, UE) through project PID2022-138957NB-I00 (R.F.-C.) as well as by the Plan Propio de Investigación de la Universidad de Sevilla, Contrato Acción II.4 PPIT (N.B.). A.C.-S. was supported by an FPU fellowship (FPU2018/00546), and A.B. was supported by an FPI fellowship (PRE2018-086522). C.F. was supported by a Miguel Servet contract (CP24_00036) from the Instituto de Salud Carlos III (ISCIII). A.C.-S. also received an EACR travel grant (EACR-907), Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

RANK signaling increases after anti-HER2 therapy contributing to the emergence of resistance in HER2-positive breast cancer

  • Sanz Moreno, Adrián
  • Palomeras, Sonia
  • Pedersen, Kim
  • Morancho, Beatriz
  • Pascual, Tomás
  • Galván, Patricia
  • Benítez, Sandra
  • Gómez Miragaya, Jorge
  • Ciscar, Marina
  • Jimenez, María
  • Pernas, Sònia
  • Petit, Anna
  • Soler, María Teresa
  • Viñas, Gemma
  • Alsaleem, Mansour
  • Rakha, Emad A.
  • Green, Andrew
  • Santamaría, Patricia G.
  • Mulder, Celine
  • Lemeer, Simone
  • Arribas, Joaquín V. (Vicente)
  • Prat Aparicio, Aleix
  • Puig, Teresa
  • González Suárez, Eva
Background: Around 15-20% of primary breast cancers are characterized by HER2 protein overexpression and/or HER2 gene amplification. Despite the successful development of anti-HER2 drugs, intrinsic and acquired resistance represents a major hurdle. This study was performed to analyze the RANK pathway contribution in HER2-positive breast cancer and anti-HER2 therapy resistance. Methods: RANK and RANKL protein expression was assessed in samples from HER2-positive breast cancer patients resistant to anti-HER2 therapy and treatment-naive patients. RANK and RANKL gene expression was analyzed in paired samples from patients treated with neoadjuvant dual HER2-blockade (lapatinib and trastuzumab) from the SOLTI-1114 PAMELA trial. Additionally, HER2-positive breast cancer cell lines were used to modulate RANK expression and analyze in vitro the contribution of RANK signaling to anti-HER2 resistance and downstream signaling. Results: RANK and RANKL proteins are more frequently detected in HER2-positive tumors that have acquired resistance to anti-HER2 therapies than in treatment-naive ones. RANK (but not RANKL) gene expression increased after dual anti-HER2 neoadjuvant therapy in the cohort from the SOLTI-1114 PAMELA trial. Results in HER2-positive breast cancer cell lines recapitulate the clinical observations, with increased RANK expression observed after short-term treatment with the HER2 inhibitor lapatinib or dual anti-HER2 therapy and in lapatinib-resistant cells. After RANKL stimulation, lapatinib-resistant cells show increased NF-κB activation compared to their sensitive counterparts, confirming the enhanced functionality of the RANK pathway in anti-HER2-resistant breast cancer. Overactivation of the RANK signaling pathway enhances ERK and NF-κB signaling and increases lapatinib resistance in different HER2-positive breast cancer cell lines, whereas RANK loss sensitizes lapatinib-resistant cells to the drug. Our results indicate that ErbB signaling is required for RANK/RANKL-driven activation of ERK in several HER2-positive cell lines. In contrast, lapatinib is not able to counteract the NF-κB activation elicited after RANKL treatment in RANK-overexpressing cells. Finally, we show that RANK binds to HER2 in breast cancer cells and that enhanced RANK pathway activation alters HER2 phosphorylation status. Conclusions: Our data support a physical and functional link between RANK and HER2 signaling in breast cancer and demonstrate that increased RANK signaling may contribute to the development of lapatinib resistance through NF-κB activation. Whether HER2-positive breast cancer patients with tumoral RANK expression might benefit from dual HER2 and RANK inhibition therapy remains to be elucidated.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Management of bone health in solid tumours: From bisphosphonates to a monoclonal antibody

  • von Moos, Roger
  • Costa, Luis
  • González Suárez, Eva
  • Terpos, Evangelos
  • Niepel, Daniela
  • Body, Jean-Jacques
Patients with solid tumours are at risk of impaired bone health from metastases and cancer therapy-induced bone loss (CTIBL). We review medical management of bone health in patients with solid tumours over the past 30 years, from first-generation bisphosphonates to the receptor activator of nuclear factor kappa B ligand (RANKL)-targeted monoclonal antibody, denosumab. In the 1980s, first-generation bisphosphonates were shown to reduce the incidence of skeletal-related events (SREs) in patients with breast cancer. Subsequently, more potent second-and third-generation bisphosphonates were developed, particularly zoledronic add (ZA). Head-to-head studies showed that ZA was significantly more effective than pamidronate for reducing SREs in patients with breast and castrate-resistant prostate cancer (CRPC), becoming the standard of care for more than a decade. The RANKL inhibitor denosumab was licensed in 2010, and head-to-head studies and integrated analyses confirmed its superiority to ZA for preventing SREs, particularly in breast cancer and CRPC. Bisphosphonates and denosumab have also been investigated for prevention of CTIBL in patients receiving hormonal therapy for breast and prostate cancer, and denosumab is licensed in this indication. Despite advances in management of bone health, several issues remain, notably the optimal time to initiate therapy, duration of therapy, and dosing frequency, and how to avoid toxicity, particularly with long-term treatment. In summary, introduction of ZA and denosumab has protected patients with bone metastasis from serious bone complications and improved their quality of life. Ongoing research will hopefully guide the optimal use of these agents to help maintain bone health in patients with solid tumours.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

European Network of Breast Development and Cancer turned 10 years: a growing family of mammary gland researchers

  • Koledova, Zuzana
  • Howard, Beatrice A.
  • Englund, Johanna
  • Bach, Karsten
  • Bentires-Alj, Mohamed
  • González Suárez, Eva
The European Network for Breast Development and Cancer (ENBDC), a worldwide network (http://www.enbdc.org/), celebrated its tenth anniversary with a fantastic meeting last March 15-17, 2018 in Weggis with 76 attendees.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

RANK links senescence to stemness in the mammary epithelia, delaying tumor onset but increasing tumor aggressiveness

  • Benítez, Sandra
  • Cordero, Alex
  • Santamaría, Patricia G.
  • Redondo Pedraza, Jaime
  • Rocha, Ana S.
  • Collado-Solé, Alejandro
  • Jimenez, María
  • Sanz Moreno, Adrian
  • Yoldi, Guillermo
  • Santos, Juliana C.
  • Benedictis, Ilaria De
  • Gómez Aleza, Clara
  • Silva Álvarez, Sabela Da
  • Troulé, Kevin
  • Gómez López, Gonzalo
  • Alcazar, Noelia
  • Palmero, Ignacio
  • Collado, Manuel
  • Serrano Marugán, Manuel
  • González Suárez, Eva
Rank signaling enhances stemness in mouse and human mammary epithelial cells (MECs) and mediates mammary tumor initiation. Mammary tumors initiated by oncogenes or carcinogen exposure display high levels of Rank and Rank pathway inhibitors have emerged as a new strategy for breast cancer prevention and treatment. Here, we show that ectopic Rank expression in the mammary epithelia unexpectedly delays tumor onset and reduces tumor incidence in the oncogene-driven Neu and PyMT models. Mechanistically, we have found that ectopic expression of Rank or exposure to Rankl induces senescence, even in the absence of other oncogenic mutations. Rank leads to DNA damage and senescence through p16/p19. Moreover, RANK-induced senescence is essential for Rank-driven stemness, and although initially translates into delayed tumor growth, eventually promotes tumor progression and metastasis. We uncover a dual role for Rank in the mammary epithelia: Rank induces senescence and stemness, delaying tumor initiation but increasing tumor aggressiveness.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

RANKL inhibitors for osteosarcoma treatment: hope and caution

  • Trinidad Alvarez, Eva Maria
  • González Suárez, Eva
Chen and collaborators propose RANKL blockade for the treatment and prevention of aggressive RANKL-overexpressing osteosarcoma (OS) in humans. Here we comment the main findings, putative applications and concerns. OS is the most common primary bone cancer, which occurs primarily in children and adolescents, severely affecting survivors’ quality of life. Current treatment for newly diagnosed OS includes three main components: preoperative chemotherapy, surgical resection, and postoperative chemotherapy (1). This strategy has improved the outcome of patients with localized OS. However, patients with advanced, metastatic, and recurrent OSs continue to experience a quite poor prognosis. After aggressive treatment with both surgery and chemotherapy, the 5-year survival rate for OS patients with localized disease is about 65%, whereas it is less than 20% for patients with metastases. The use of adjuvant chemotherapy provides no survival advantage for patients with pulmonary metastases (2). So that, it is of particular importance to develop molecularly targeted therapy to treat patients with this metastatic bone malignancy, on the basis of in-depth understanding of signaling mechanisms involved in OS tumorigenesis.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

The altered transcriptome and DNA methylation profiles of docetaxel resistance in breast cancer PDX models

  • Gómez Miragaya, Jorge
  • Moran, Sebastian
  • Calleja Cervantes, Maria E.
  • Collado-Solé, Alejandro
  • Paré, Laia
  • Gómez, Antonio
  • Serra Elizalde, Violeta
  • Dobrolecki, Lacey E.
  • Lewis, Michael T.
  • Diaz-Lagares, Angel
  • Eroles, Pilar
  • Prat Aparicio, Aleix
  • Esteller, Manel
  • González Suárez, Eva
Taxanes are standard therapy in clinical practice for metastatic breast cancer; however, primary or acquired chemoresistance are a common cause of mortality. Breast cancer patient-derived xenografts (PDX) are powerful tools for the study of cancer biology and drug treatment response. Specific DNA methylation patterns have been associated to different breast cancer subtypes but its association with chemoresistance remains unstudied. Aiming to elucidate docetaxel resistance mechanisms, we performed genome-wide DNA methylation in breast cancer PDX models, including luminal and triple-negative breast cancer (TNBC) models sensitive to docetaxel, their matched models after emergence of chemoresistance and residual disease after short-term docetaxel treatment. We found that DNA methylation profiles from breast cancer PDX models maintain the subtype-specific methylation patterns of clinical samples. Two main DNA methylation clusters were found in TNBC PDX and remain stable during the emergence of docetaxel resistance; however, some genes/pathways were differentially methylated according to docetaxel response. A DNA methylation signature of resistance able to segregate TNBC based on chemotherapy response was identified. Transcriptomic profiling of selected sensitive/resistant pairs and integrative analysis with methylation data demonstrated correlation between some differentially methylated and expressed genes in docetaxel-resistant TNBC PDX models. Multiple gene expression changes were found after the emergence of docetaxel resistance in TNBC. DNA methylation and transcriptional changes identified between docetaxel-sensitive and -resistant TNBC PDX models or residual disease may have predictive value for chemotherapy response in TNBC. IMPLICATIONS: Subtype-specific DNA methylation patterns are maintained in breast cancer PDX models. While no global methylation changes were found, we uncovered differentially DNA methylated and expressed genes/pathways associated with the emergence of docetaxel resistance in TNBC.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Interrogating open issues in cancer precision medicine with patient-derived xenografts

  • Byrne, Annette T.
  • Alférez, Denis G.
  • Amant, Frédéric
  • Annibali, Daniela
  • Arribas, Joaquín V. (Vicente)
  • Biankin, Andrew V.
  • Bruna, Alejandra
  • Budinská, Eva
  • Caldas, Carlos
  • Chang, David K.
  • Clarke, Robert B.
  • Clevers, Hans
  • Coukos, George
  • Dangles Marie, Virginie
  • Eckhardt, S. Gail
  • González Suárez, Eva
  • Hermans, Els
  • Hidalgo, Manuel
  • Jarzabek, Monika A.
  • Jong, Steven de
  • Jonkers, Jos
  • Kemper, Kristel
  • Lanfrancone, Luisa
  • Mælandsmo, Gunhild Mari
  • Marangoni, Elisabetta
  • Marine, Jean-Christophe
  • Medico, Enzo
  • Norum, Jens Henrik
  • Palmer, Héctor G.
  • Peeper, Daniel S.
  • Pelicci, Pier Giuseppe
  • Piris Gimenez, Alejandro
  • Roman Roman, Sergio
  • Rueda, Oscar M.
  • Seoane Suárez, Joan
  • Serra Elizalde, Violeta
  • Soucek, Laura
  • Vanhecke, Dominique
  • Villanueva Garatachea, Alberto
  • Vinolo, Emilie
  • Bertotti, Andrea
  • Trusolino, Livio
Patient-derived xenografts (PDXs) have emerged as an important platform to elucidate new treatments and biomarkers in oncology. PDX models are used to address clinically relevant questions, including the contribution of tumour heterogeneity to therapeutic responsiveness, the patterns of cancer evolutionary dynamics during tumour progression and under drug pressure, and the mechanisms of resistance to treatment. The ability of PDX models to predict clinical outcomes is being improved through mouse humanization strategies and the implementation of co-clinical trials, within which patients and PDXs reciprocally inform therapeutic decisions. This Opinion article discusses aspects of PDX modelling that are relevant to these questions and highlights the merits of shared PDX resources to advance cancer medicine from the perspective of EurOPDX, an international initiative devoted to PDX-based research.